ZADAXIN Trademark

Trademark Overview

On Friday, July 10, 1992, a trademark application was filed for ZADAXIN with the United States Patent and Trademark Office. The USPTO has given the ZADAXIN trademark a serial number of 74293092. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, January 17, 2025. This trademark is owned by SciClone Pharmaceuticals, Inc.. The ZADAXIN trademark is filed in the Pharmaceutical Products category with the following description:

injectable pharmaceutical preparations used in the treatment of, or to provide immunomodulation in viral diseases, such as hepatitis; cancer; and immune deficiency states
zadaxin

General Information

Serial Number74293092
Word MarkZADAXIN
Filing DateFriday, July 10, 1992
Status710 - CANCELLED - SECTION 8
Status DateFriday, January 17, 2025
Registration Number1843447
Registration DateTuesday, July 5, 1994
Mark Drawing1 - Typeset: Word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, December 29, 1992

Trademark Statements

Goods and Servicesinjectable pharmaceutical preparations used in the treatment of, or to provide immunomodulation in viral diseases, such as hepatitis; cancer; and immune deficiency states

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes018
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, January 17, 2025
Primary Code005
First Use Anywhere DateMonday, March 15, 1993
First Use In Commerce DateMonday, March 15, 1993

Trademark Owner History

Party NameSCICLONE PHARMACEUTICALS, INC.
Party Type31 - New Owner After Registration
Legal Entity Type03 - Corporation
AddressFoster City, CA 944042125
Party NameSciClone Pharmaceuticals, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSan Mateo, CA 94404
Party NameSciClone Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Mateo, CA 94404
Party NameSciClone Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Mateo, CA 94404

Trademark Events

Event DateEvent Description
Tuesday, September 15, 1992ASSIGNED TO EXAMINER
Wednesday, September 16, 1992APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, November 27, 1992NOTICE OF PUBLICATION
Tuesday, December 29, 1992PUBLISHED FOR OPPOSITION
Wednesday, September 22, 1993ASSIGNED TO EXAMINER
Tuesday, January 11, 1994NOA MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 15, 1994USE AMENDMENT FILED
Friday, March 25, 1994STATEMENT OF USE PROCESSING COMPLETE
Friday, April 15, 1994ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, July 5, 1994REGISTERED-PRINCIPAL REGISTER
Thursday, June 22, 2000REGISTERED - SEC. 8 (6-YR) & SEC. 15 FILED
Tuesday, October 24, 2000REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Monday, May 3, 2004REGISTERED - COMBINED SECTION 8 (10-YR) & SEC. 9 FILED
Tuesday, July 6, 2004REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Tuesday, July 6, 2004REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Tuesday, July 6, 2004REGISTERED - COMBINED SECTION 8 (10-YR) & SEC. 9 FILED
Friday, August 12, 2005ASSIGNED TO PARALEGAL
Tuesday, February 17, 2009TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, February 17, 2009APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, March 31, 2010CASE FILE IN TICRS
Wednesday, July 2, 2014TEAS SECTION 8 & 9 RECEIVED
Tuesday, August 5, 2014POST REGISTRATION ACTION MAILED - SEC. 8 & 9
Tuesday, February 3, 2015TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
Wednesday, April 22, 2015REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Wednesday, April 22, 2015REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS)
Wednesday, April 22, 2015NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Wednesday, July 5, 2023COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Friday, January 17, 2025CANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9

Related Keywords

zadaxin hepatitis such cancer immune states deficiency diseases viral preparations pharmaceutical